| 1. |
|
|
| 2. |
- Kumar, Pravin, et al.
(författare)
-
Phylogenomic evaluation of Mangrovimicrobium sediminis gen. nov. sp. nov., the first nitrogen fixing member of the family Halieaceae adapted to mangrove habitat and reclassification of Halioglobus pacificus to Pseudohaliglobus pacificus comb. nov.
- 2024
-
Ingår i: Science of the Total Environment. - : Elsevier. - 0048-9697 .- 1879-1026. ; 933
-
Tidskriftsartikel (refereegranskat)abstract
- The taxonomic position and genomic characteristics of a nitrogen fixing and polymer degrading marine bacterium, strain SAOS 164 isolated from a mangrove sediment sample was investigated. Sequence analysis based on 16S rRNA gene identified it as a member of family Halieaceae with closest similarity to Haliea salexigens DSM 19537T (96.3 %), H. alexandrii LZ-16-2T (96.2 %) and Parahaliea maris HSLHS9T (96.0 %) but was distantly related to the genera Haliea, Parahaliea and Halioglobus in phylogenetic trees. In order to ascertain the exact taxonomic position, phylogeny based on RpoBC proteins, whole genome, core and orthologous genes, and comparative analysis of metabolic potential retrieved the strain in an independent lineage clustering along with the genera Halioglobus, Pseudohalioglobus and Seongchinamella. Further, various genome based delimitation parameters represented by mol % GC content, percentage of conserved proteins (POCP), and amino acid identity (AAI) along with chemotaxonomic markers (i.e. fatty acids and polar lipids) supported the inferences of genome based phylogeny and indicated that the strain SAOS 164 belongs to a novel genus. The genome was mapped to 4.8 Mb in size with 65.1 % DNA mol% G + C content. In-silico genomic investigation and phenotyping revealed diverse metabolite genes/pathways related to polymer hydrolysis, nitrogen fixation, light induced growth, carbohydrate, sulfur, phosphorus and amino acid metabolism, virulence factors, defense mechanism, and stress-responsive elements facilitating survival in the mangrove habitat. Based on polyphasic taxonomic approach including genome analyses, a novel genus Mangrovimicrobium sediminis gen. nov. sp. nov. (=SAOS 164T = MTCC 12907T = KCTC 52755T = JCM 32136T) is proposed. Additionally, the reclassification of Halioglobus pacificus (=DSM 27932T = KCTC 23430T = S1–72T) to Pseudhalioglobus pacificus comb. nov. is also proposed.
|
|
| 3. |
- Rana, Pravin Kumar, et al.
(författare)
-
Prediction of Sea Ice Edge in the Antarctic Using GVF Snake Model
- 2011
-
Ingår i: Journal of the Geological Society of India. - : Springer Science and Business Media LLC. - 0016-7622 .- 0974-6889. ; 78:2, s. 99-108
-
Tidskriftsartikel (refereegranskat)abstract
- Antarctic sea ice cover plays an important role in shaping the earth's climate, primarily by insulating the ocean from the atmosphere and increasing the surface albedo. The convective processes accompanied with the sea ice formation result bottom water formation. The cold and dense bottom water moves towards the equator along the ocean basins and takes part in the global thermohaline circulation. Sea ice edge is a potential indicator of climate change. Additionally, fishing and commercial shipping activities as well as military submarine operations in the polar seas need reliable ice edge information. However, as the sea ice edge is unstable in time, the temporal validity of the estimated ice edge is often shorter than the time required to transfer the information to the operational user. Hence, an accurate sea ice edge prediction as well as determination is crucial for fine-scale geophysical modeling and for near-real-time operations. In this study, active contour modelling (known as Snake model) and non-rigid motion estimation techniques have been used for predicting the sea ice edge (SIE) in the Antarctic. For this purpose the SIE has been detected from sea ice concentration derived using special sensor microwave imager (SSM/I) observations. The 15% sea ice concentration pixels are being taken as the edge pixel between ice and water. The external force, gradient vector flow (GVF), of SIE for total the Antarctic region is parameterised for daily as well as weekly data set. The SIE is predicted at certain points using a statistical technique. These predicted points have been used to constitute a SIE using artificial intelligence technique, the gradient vector flow (GVF). The predicted edge has been validated with that of SSM/I. It is found that all the major curvatures have been captured by the predicated edge and it is in good agreement with that of the SSM/I observation.
|
|
| 4. |
- Ray, Sumit Kumar, et al.
(författare)
-
Modern analogue to past coseismic ground uplift in North Andaman, India
- 2021
-
Ingår i: Catena (Cremlingen. Print). - : Elsevier. - 0341-8162 .- 1872-6887. ; 205
-
Tidskriftsartikel (refereegranskat)abstract
- Dynamics of surface geological processes, triggered by coseismic ground uplift following the 2004 Sumatra-Andaman earthquake (M-w > 9.2), provide a modern analogue for assessing the paleoseismic significance of an enigmatic subsurface peat occurrence within beach sands in the western coast of North Andaman Island. The megathrust earthquake uplifted vast stretches of coastal intertidal zones to supratidal levels. As a result, intertidal flora, including mangroves, desiccated and perished. Mass mortality of the flora continued even three years after the earthquake and generated a large volume of forest debris. Coastal waves pushed the debris to the high tide line where the accumulated debris would be gradually buried, and would subsequently transform into linear peat bodies keeping a record of the seismic event in 2004. Accordingly, we have interpreted a linear strand-parallel peat occurrence in beach sand as a record of earlier mass mortality of plants likely associated with a coseismic ground uplift. Stable isotope studies indicate that local intertidal flora is the source of the peat organic matter. Moreover, the 1817 CE calibrated mean AMS radiocarbon age of the peat suggests recurrence of a megathrust earthquake in the Andaman subduction zone about 200 years ago.
|
|
| 5. |
- Georgakis, Apostolos, et al.
(författare)
-
3DTV Exploration Experiments (EE1 & EE4) on the Lovebird1 Data Set
- 2009
-
Rapport (populärvet., debatt m.m.)abstract
- This contribution describes the results to two sets of 3DTV exploration experiments undertaken by Ericsson using the Lovebird 1 sequence defined in the last MPEG meeting in London (see w10720). These sets cover both EE1 for depth estimation and view synthesis and EE4 for coding efficiency.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Granholm, Anders, et al.
(författare)
-
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
- 2022
-
Ingår i: Intensive Care Medicine. - : SPRINGER. - 0342-4642 .- 1432-1238. ; 48:1, s. 45-55
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID STEROID 2 trial. In the primary, conventional analyses, the predefined statistical significance thresholds were not reached. We conducted a pre-planned Bayesian analysis to facilitate probabilistic interpretation. Methods We analysed outcome data within 90 days in the intention-to-treat population (data available in 967 to 982 patients) using Bayesian models with various sensitivity analyses. Results are presented as median posterior probabilities with 95% credible intervals (CrIs) and probabilities of different effect sizes with 12 mg dexamethasone. Results The adjusted mean difference on days alive without life support at day 28 (primary outcome) was 1.3 days (95% CrI -0.3 to 2.9; 94.2% probability of benefit). Adjusted relative risks and probabilities of benefit on serious adverse reactions was 0.85 (0.63 to 1.16; 84.1%) and on mortality 0.87 (0.73 to 1.03; 94.8%) at day 28 and 0.88 (0.75 to 1.02; 95.1%) at day 90. Probabilities of benefit on days alive without life support and days alive out of hospital at day 90 were 85 and 95.7%, respectively. Results were largely consistent across sensitivity analyses, with relatively low probabilities of clinically important harm with 12 mg on all outcomes in all analyses. Conclusion We found high probabilities of benefit and low probabilities of clinically important harm with dexamethasone 12 mg versus 6 mg daily in patients with COVID-19 and severe hypoxaemia on all outcomes up to 90 days.
|
|
| 9. |
- Granholm, Anders, et al.
(författare)
-
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis
- 2021
-
Ingår i: Acta Anaesthesiologica Scandinavica. - : WILEY. - 0001-5172 .- 1399-6576. ; 65:5, s. 702-710
-
Tidskriftsartikel (refereegranskat)abstract
- Background Coronavirus disease 2019 (COVID-19) can lead to severe hypoxic respiratory failure and death. Corticosteroids decrease mortality in severely or critically ill patients with COVID-19. However, the optimal dose remains unresolved. The ongoing randomised COVID STEROID 2 trial investigates the effects of higher vs lower doses of dexamethasone (12 vs 6 mg intravenously daily for up to 10 days) in 1,000 adult patients with COVID-19 and severe hypoxia. Methods This protocol outlines the rationale and statistical methods for a secondary, pre-planned Bayesian analysis of the primary outcome (days alive without life support at day 28) and all secondary outcomes registered up to day 90. We will use hurdle-negative binomial models to estimate the mean number of days alive without life support in each group and present results as mean differences and incidence rate ratios with 95% credibility intervals (CrIs). Additional count outcomes will be analysed similarly and binary outcomes will be analysed using logistic regression models with results presented as probabilities, relative risks and risk differences with 95% CrIs. We will present probabilities of any benefit/harm, clinically important benefit/harm and probabilities of effects smaller than pre-defined clinically minimally important differences for all outcomes analysed. Analyses will be adjusted for stratification variables and conducted using weakly informative priors supplemented by sensitivity analyses using sceptic priors. Discussion This secondary, pre-planned Bayesian analysis will supplement the primary, conventional analysis and may help clinicians, researchers and policymakers interpret the results of the COVID STEROID 2 trial while avoiding arbitrarily dichotomised interpretations of the results. Trial registration ClinicalTrials.gov: NCT04509973; EudraCT: 2020-003363-25.
|
|
| 10. |
- Granholm, Anders, et al.
(författare)
-
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
- 2022
-
Ingår i: Intensive Care Medicine. - : SPRINGER. - 0342-4642 .- 1432-1238. ; 48, s. 580-589
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.
|
|
